In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...